SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Radius Health, Inc. – RDUS

NEW YORK, NY / ACCESSWIRE / July 21, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Radius Health, Inc. (“Radius Health” or the “Company”) (NASDAQ: RDUS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Radius Health and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 21, 2015, Radius announced that the FDA had denied the company’s request for breakthrough therapy designation for the company’s osteoporosis drug, abaloparatide-SC.

On this news, the company’s shares have fallen 5.07, or 6.48%, in after-hours trading, on July 21, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 430751